This book extensively reviews Paraneoplastic Neurological Syndromes in light of the most recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to causing diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. These two new developments have not been addressed in other volumes available on the market.
Section 1 focuses on immunological defense mechanisms against tumors. Besides investigating the pathogenetic mechanisms of these disorders, this section will also explore what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy is teaching us in terms of immunopathogenesis. The second section will present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ and muscle. These chapters will, however, be preceded by an epidemiological analysis and a chapter describing the clinical approach to patients with these disorders. Consideration will also be given in specific chapters to general therapeutic strategies and the techniques used to search for diagnostically relevant autoantibodies. Presentation of the individual diseases will be followed by a third section investigating the role of antibody markers, presented in three chapters differentiating cytoplasmic, nuclear and neuronal cell surface reactivities.
The innovative component of the final two sections compared to previously published volumes lies in their presentation of the profile of paraneoplastic diseases by tumor type. Special attention will be given to thymoma (involved particularly with novel antibodies against surface antigens), and neuroendocrine tumours, which are as yet comparatively unexplored in the literature. Lastly, a clinical update will be provided on gynecological, hematological and testicular malignancies.
The last section will address side effects of the new immuno-oncological drugs increasingly used in cancer therapy. The high number of neurological complications that occur when tumor checkpoints are inhibited against immune defences provides the ideal experimental model for understanding the pathogenesis of these diseases.
1. Section I: Introduction and overview - p. xii 2. Chapter 1: Introduction and overview of immunopathological mechanisms and future directions - p. 3 3. Chapter 2: Changing landscape in the field of paraneoplastic neurology: Personal perspectives over a 35-year career - p. 24 4. Chapter 3: Pathogenesis and immunopathology of paraneoplastic disorders - p. 35 5. Section II: Paraneoplastic neurologic syndromes - p. 54 6. Chapter 4: Epidemiology of paraneoplastic neurologic syndromes - p. 58 7. Chapter 5: Clinical approach to diagnosis of paraneoplastic neurologic syndromes - p. 84 8. Chapter 6: Overview of treatment strategies in paraneoplastic neurological syndromes - p. 100 9. Chapter 7: Evolution of methods to detect paraneoplastic antibodies - p. 123 10. Chapter 8: Paraneoplastic encephalitis - p. 131 11. Chapter 9: Autoimmune and paraneoplastic seizures - p. 153 12. Chapter 10: Paraneoplastic cerebellar and brainstem disorders - p. 173 13. Chapter 11: Paraneoplastic/autoimmune myelopathies - p. 193 14. Chapter 12: Paraneoplastic vision loss - p. 203 15. Chapter 13: Paraneoplastic movement disorders - p. 214 16. Chapter 14: Movement disorders associated with pediatric encephalitis - p. 229 17. Chapter 15: Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders - p. 239 18. Chapter 16: Paraneoplastic autonomic neuropathies and GI dysmotility - p. 275 19. Chapter 17: Myasthenia gravis—Pathophysiology, diagnosis, and treatment - p. 283 20. Chapter 18: Lambert-Eaton myasthenic syndrome - p. 307 21. Chapter 19: Paraneoplastic myopathies - p. 327 22. Section III: Paraneoplastic autoantibodies - p. 332 23. Chapter 20: Paraneoplastic antibodies targeting intracellular antigens - p. 337 24. Chapter 21: Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes - p. 347 25. Chapter 22: Optimizing the diagnostic performance of neural antibody testing for paraneoplastic and autoimmune encephalitis in clinical practice - p. 376 26. Section IV: Paraneoplastic neurological and autoantibody accompaniments of cancer - p. 382 27. Chapter 23: Paraneoplastic autoimmune neurologic disorders associated with thymoma - p. 385 28. Chapter 24: Paraneoplastic neurologic manifestations of neuroendocrine tumors - p. 397 29. Chapter 25: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies - p. 409 30. Chapter 26: Hematologic malignancies and hematopoietic stem cell transplantation - p. 419 31. Chapter 27: Paraneoplastic neurologic syndrome and autoantibody accompaniments of germ cell tumors - p. 431 32. Section V: Neurological complications of cancer immunotherapy - p. 445 33. Chapter 28: Neurologic manifestations of autoimmunity with immune checkpoint inhibitors - p. 449 34. Index - p. 465
This book extensively reviews Paraneoplastic Neurological Syndromes in light of the most recent descriptions of autoantibodies against neuronal cell surface antigens (only partly associated with paraneoplastic disorders) and the introduction of new immuno-oncological drugs that can contribute to causing diseases that are pathogenetically indistinguishable from paraneoplastic syndromes. These two new developments have not been addressed in other volumes available on the market.
Section 1 focuses on immunological defense mechanisms against tumors. Besides investigating the pathogenetic mechanisms of these disorders, this section will also explore what the introduction of new drugs used in immune checkpoint inhibitor cancer therapy is teaching us in terms of immunopathogenesis. The second section will present individual syndromes (phenotypical clinical manifestations) of the CNS, PNS, NMJ and muscle. These chapters will, however, be preceded by an epidemiological analysis and a chapter describing the clinical approach to patients with these disorders. Consideration will also be given in specific chapters to general therapeutic strategies and the techniques used to search for diagnostically relevant autoantibodies. Presentation of the individual diseases will be followed by a third section investigating the role of antibody markers, presented in three chapters differentiating cytoplasmic, nuclear and neuronal cell surface reactivities.
The innovative component of the final two sections compared to previously published volumes lies in their presentation of the profile of paraneoplastic diseases by tumor type. Special attention will be given to thymoma (involved particularly with novel antibodies against surface antigens), and neuroendocrine tumours, which are as yet comparatively unexplored in the literature. Lastly, a clinical update will be provided on gynecological, hematological and testicular malignancies.
The last section will address side effects of the new immuno-oncological drugs increasingly used in cancer therapy. The high number of neurological complications that occur when tumor checkpoints are inhibited against immune defences provides the ideal experimental model for understanding the pathogenesis of these diseases.
1. Section I: Introduction and overview - p. xii 2. Chapter 1: Introduction and overview of immunopathological mechanisms and future directions - p. 3 3. Chapter 2: Changing landscape in the field of paraneoplastic neurology: Personal perspectives over a 35-year career - p. 24 4. Chapter 3: Pathogenesis and immunopathology of paraneoplastic disorders - p. 35 5. Section II: Paraneoplastic neurologic syndromes - p. 54 6. Chapter 4: Epidemiology of paraneoplastic neurologic syndromes - p. 58 7. Chapter 5: Clinical approach to diagnosis of paraneoplastic neurologic syndromes - p. 84 8. Chapter 6: Overview of treatment strategies in paraneoplastic neurological syndromes - p. 100 9. Chapter 7: Evolution of methods to detect paraneoplastic antibodies - p. 123 10. Chapter 8: Paraneoplastic encephalitis - p. 131 11. Chapter 9: Autoimmune and paraneoplastic seizures - p. 153 12. Chapter 10: Paraneoplastic cerebellar and brainstem disorders - p. 173 13. Chapter 11: Paraneoplastic/autoimmune myelopathies - p. 193 14. Chapter 12: Paraneoplastic vision loss - p. 203 15. Chapter 13: Paraneoplastic movement disorders - p. 214 16. Chapter 14: Movement disorders associated with pediatric encephalitis - p. 229 17. Chapter 15: Paraneoplastic neuropathies and peripheral nerve hyperexcitability disorders - p. 239 18. Chapter 16: Paraneoplastic autonomic neuropathies and GI dysmotility - p. 275 19. Chapter 17: Myasthenia gravis—Pathophysiology, diagnosis, and treatment - p. 283 20. Chapter 18: Lambert-Eaton myasthenic syndrome - p. 307 21. Chapter 19: Paraneoplastic myopathies - p. 327 22. Section III: Paraneoplastic autoantibodies - p. 332 23. Chapter 20: Paraneoplastic antibodies targeting intracellular antigens - p. 337 24. Chapter 21: Antibodies to neural cell surface and synaptic proteins in paraneoplastic neurologic syndromes - p. 347 25. Chapter 22: Optimizing the diagnostic performance of neural antibody testing for paraneoplastic and autoimmune encephalitis in clinical practice - p. 376 26. Section IV: Paraneoplastic neurological and autoantibody accompaniments of cancer - p. 382 27. Chapter 23: Paraneoplastic autoimmune neurologic disorders associated with thymoma - p. 385 28. Chapter 24: Paraneoplastic neurologic manifestations of neuroendocrine tumors - p. 397 29. Chapter 25: Paraneoplastic neurologic syndrome associated with gynecologic and breast malignancies - p. 409 30. Chapter 26: Hematologic malignancies and hematopoietic stem cell transplantation - p. 419 31. Chapter 27: Paraneoplastic neurologic syndrome and autoantibody accompaniments of germ cell tumors - p. 431 32. Section V: Neurological complications of cancer immunotherapy - p. 445 33. Chapter 28: Neurologic manifestations of autoimmunity with immune checkpoint inhibitors - p. 449 34. Index - p. 465
